⌘K

06:20:00·3h

PRRelease

New Study Highlights Safety and Efficacy Profile of Haemonetics' VASCADE MVP® XL in Large-Bore Venous Access Closure Procedures

HAE· Haemonetics Corporation

Health Care

Original source

Companies

HAE
Haemonetics Corporation
Health Care

Recent analyst ratings

Dec 15UpdateNeedham-
Dec 11UpdateCitigroup$88.00
Aug 11UpdateRaymond James$78.00
Aug 8UpdateAnalyst$62.00
Aug 8UpdateBarrington Research$86.00
Jul 9UpdateCitigroup$90.00

Related

PR22d
Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2026 Results: May 7, 2026
PR24d
Haemonetics Receives FDA Approval for Expanded Labeling of the VASCADE MVP® XL Venous Vascular Closure System
SEC28d
Amendment: SEC Form SCHEDULE 13G/A filed by Haemonetics Corporation
SEC52d
Haemonetics Corporation filed SEC Form 8-K: Regulation FD Disclosure
PR59d
Haemonetics Receives FDA Clearance for NexSys® PCS Plasma Collection System with Persona® PLUS Technology
PR62d
Haemonetics to Present at Raymond James 47th Annual Institutional Investors Conference
SEC70d
Haemonetics Corporation filed SEC Form 8-K: Regulation FD Disclosure
SEC78d
SEC Form 10-Q filed by Haemonetics Corporation